In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Medical Device

Start-Up Previews, November 2012

Executive Summary

This Month's Profile Group: Anti-Infective Start-Ups See Opportunity In An Epidemiological Nightmare features profiles of Arasanis, ContraFect and Fedora Pharmaceuticals. Plus these Start-Ups Across Health Care: Arrowhead Medical Technologies, Covagen, Integral Spine Solutions, Maxillent, and Vaccibody.

You may also be interested in...



Maxillent Ltd.

Maxillent Ltd. is developing an alternative to invasive sinus lift procedures for augmenting bone prior to placing dental implants. Its iRaise is a closed sinus-lift implant system that not only augments the bone, but also provides a dental implant, in one simultaneous minimally invasive procedure.

Arrowhead Medical Device Technologies LLC

Arrowhead Medical Device Technologies LLC has developed the ARROW-LOK Digital Fusion System for correcting hammertoes. The one piece device consists of a stainless-steel cylindrical shaft with opposing 3-D arrowheads at each end to provide stable fixation.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical Medical Device
Latest Headlines

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

South Korea Sees Pharma Leadership Transition

FDA-EMA Advice Pilot For Complex Generics: What Does Industry Have To Say?

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

See All
UsernamePublicRestriction

Register

IV003771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By